J3304Inj triamcinolone ace xr 1mg
Published CMS Medicare Part B payment-limit context for J3304, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$19.28
per 1 MG · Medicare Part B
Up 3.5%from $18.636 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$19.4948$17.5312
2024-Q4: $17.746; 2025-Q1: $17.998; 2025-Q2: $18.007; 2025-Q3: $18.209; 2025-Q4: $18.297; 2026-Q1: $18.579; 2026-Q2: $18.636; 2026-Q3: $19.28
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Triamcinolone Acetonide Extended-Release Injectable Suspension ingredient family (FDA data as of August 20, 2026).
Zilretta
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.